Decoy Therapeutics (DCOY) Enterprise Value (2015 - 2026)
Decoy Therapeutics (DCOY) posted quarterly Enterprise Value of -$7.8 million for Q1 2026, down 334.87% year-over-year from $3.3 million in Q1 2025, and up 26.98% quarter-over-quarter from -$10.7 million in Q4 2025.
Decoy Therapeutics (DCOY) Enterprise Value (2015 - 2026) Analysis & Trends
Decoy Therapeutics (DCOY) has reported Enterprise Value for 12 consecutive years, with -$7.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 334.87% year-over-year to -$7.8 million; the TTM figure through Mar 2026 stood at -$7.8 million (down 334.87% YoY), while the FY2025 annual figure was -$10.7 million, down 339.92% from the prior year.
- Enterprise Value climbed to -$7.8 million in Q1 2026 per DCOY's latest filing, from -$10.7 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$794886.0 in Q2 2025 and bottomed at -$24.2 million in Q1 2022.
- Historically, Enterprise Value has averaged -$8.8 million across 5 years, with a median of -$7.6 million in 2023.
- On a YoY basis, Enterprise Value climbed as much as 75.71% in 2025 and fell as far as 339.92% in 2025.
- Decoy Therapeutics' Enterprise Value stood at -$12.1 million in 2022, then soared by 51.27% to -$5.9 million in 2023, then surged by 58.74% to -$2.4 million in 2024, then slumped by 339.92% to -$10.7 million in 2025, then advanced by 26.98% to -$7.8 million in 2026.
- Business Quant data shows DCOY's Enterprise Value at -$7.8 million in Q1 2026, -$10.7 million in Q4 2025, and -$4.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | 2.12 Bn |
| 10 | Decoy Therapeutics | 1.73 Mn | 1.73 Mn | - | -8.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.29 Mn |
| Mar 31, 2026 | -7.82 Mn |
| Dec 31, 2025 | -10.71 Mn |
| Sep 30, 2025 | -4.81 Mn |
| Jun 30, 2025 | -794,886.00 |
| Mar 31, 2025 | -1.80 Mn |
| Dec 31, 2024 | -2.43 Mn |
| Sep 30, 2024 | -3.28 Mn |
| Jun 30, 2024 | -3.27 Mn |
| Mar 31, 2024 | -4.37 Mn |
| Dec 31, 2023 | -5.90 Mn |
| Sep 30, 2023 | -7.58 Mn |
| Jun 30, 2023 | -11.54 Mn |
| Mar 31, 2023 | -9.27 Mn |
| Dec 31, 2022 | -12.11 Mn |
| Sep 30, 2022 | -16.80 Mn |
| Jun 30, 2022 | -22.65 Mn |
| Mar 31, 2022 | -24.19 Mn |
| Dec 31, 2021 | -29.21 Mn |
| Sep 30, 2021 | -31.90 Mn |